Heart Failure in Cardiac Amyloidosis: Suspecting and Diagnosing Transthyretin Amyloid Cardiomyopathy in Underdiagnosed Populations at Risk for Heart Failure-ASNC Amyloid Practice Points

ASNC Amyloid Practice Points

Pdf Summary

The document discusses the use of 99mTechnetium-pyrophosphate (99mTc-PYP) imaging for assessing cardiac transthyretin amyloidosis. Cardiac ATTR amyloidosis is highlighted as an often underdiagnosed cause of heart failure, primarily affecting older individuals. The imaging method is considered valuable in differentiating between cardiac ATTR and AL amyloidosis. Patient selection criteria for the imaging procedure are outlined, emphasizing individuals with unexplained heart failure or thickened ventricles. The document details the imaging procedure, preparing the radiotracer, and standardized acquisition recommendations. It also provides guidelines for interpreting the images, including quantifying myocardial 99mTc-PYP uptake. Recommendations for reporting and billing are included, along with references supporting the information. The importance of excluding other causes of myocardial injury is emphasized. The document concludes with acknowledgments and contributors to the guidelines. Overall, the document serves as a comprehensive resource for healthcare professionals involved in diagnosing and managing cardiac amyloidosis through imaging techniques.

Keywords

99mTechnetium-pyrophosphate imaging

cardiac transthyretin amyloidosis

heart failure

cardiac ATTR amyloidosis

AL amyloidosis

patient selection criteria

imaging procedure

radiotracer preparation

myocardial uptake quantification

billing guidelines